Open Access
- 28 May 2012
- journal article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 31 (1) , 50
Abstract
New chemotherapic agents and new protocols in oncology have led to an increasing survival rate in patients affected by tumors. However, this increased use has been accompanied by a growth in the incidence of cutaneous side effects and a worsening of patients’ quality of life. Appropriate management of skin toxicity associated with chemotherapic agents is therefore necessary for suitable drug administration and to improve quality of life and clinical outcomes.Keywords
This publication has 16 references indexed in Scilit:
- Sorafenib‐induced premalignant and malignant skin lesionsInternational Journal of Dermatology, 2011
- Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenibJournal of Experimental & Clinical Cancer Research, 2010
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with SorafenibThe Oncologist, 2010
- Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimenIndian Journal of Pharmacology, 2010
- Skin toxicities associated with epidermal growth factor receptor inhibitorsTargeted Oncology, 2009
- The growing importance of skin toxicity in EGFR inhibitor therapy.2009
- Do Patients Die from Rashes from Epidermal Growth Factor Receptor Inhibitors? A Systematic Review to Help Counsel Patients About Holding TherapyThe Oncologist, 2008
- Candidate mechanisms for capecitabine‐related hand–foot syndromeBritish Journal of Clinical Pharmacology, 2008
- Chemotherapeutic agents and the skin: An updateJournal of the American Academy of Dermatology, 2008
- Hiperpigmentación secundaria a capecitabinaActas Dermo-Sifiliograficas, 2007